No connection

Search Results

RGNX

BEARISH
$9.49 Live
REGENXBIO Inc. · NASDAQ
Target $27.82 (+193.1%)
$5.85 52W Range $16.19
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026
Market cap
$489.85M
P/E
N/A
ROE
-107.0%
Profit margin
-113.8%
Debt/Equity
2.54
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
RGNX exhibits significant financial fragility, evidenced by a weak Piotroski F-Score of 3/9 and a lack of deterministic value markers like the Graham Number. While the company shows strong top-line revenue growth of 43%, this is offset by severe profitability deficits, including a profit margin of -113.75% and consistent earnings misses over the last four quarters. The stark divergence between the current price ($9.49) and the analyst target ($27.82) suggests a speculative valuation based on future pipeline success rather than current fundamentals. High debt-to-equity (2.54) and bearish insider sentiment further compound the risk profile.

Key Strengths

Strong year-over-year revenue growth of 43%
Healthy short-term liquidity with a current ratio of 2.38
Significant positive analyst sentiment with a target price of $27.82
Recent 1-year price recovery of +59.8%
Strong Q/Q revenue momentum

Key Risks

Severe operational losses with an operating margin of -189.99%
Weak financial health indicated by a Piotroski F-Score of 3/9
High leverage with a Debt/Equity ratio of 2.54
Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)
Negative long-term price trajectory (5Y change of -72%)
AI Fair Value Estimate
Based on comprehensive analysis
$14.5
+52.8% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
28
Weak
Value
20
Future
65
Past
30
Health
25
Dividend
0
AI Verdict
Speculative/High Risk
Key drivers: Revenue growth, Piotroski F-Score, Profitability margins, Insider selling
Confidence
90%
Value
20/100

P/E is N/A; Forward P/E is negative (-4.32), indicating no current path to profitability.

Positives
  • Low P/S ratio relative to some high-growth biotech peers
Watchpoints
  • No Graham Number due to negative earnings
  • High Price/Book ratio of 4.70
Future
65/100

Growth is concentrated in revenue, not earnings.

Positives
  • 43% YoY Revenue growth
  • Aggressive analyst price targets
Watchpoints
  • Negative EPS growth trends
  • High cash burn implied by margins
Past
30/100

Historical performance shows a pattern of volatility and value destruction.

Positives
  • Recent 1-year recovery
Watchpoints
  • 5-year return of -72%
  • Chronic earnings misses over 25 quarters
Health
25/100

Altman Z-Score not provided, but F-Score confirms fundamental weakness.

Positives
  • Current ratio > 2.0
Watchpoints
  • Piotroski F-Score 3/9 (Weak)
  • Debt/Equity of 2.54
Dividend
0/100

Typical for growth-stage biotech.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$9.49
Analyst Target
$27.82
Upside/Downside
+193.1%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for RGNX and closest competitors.

Updated 2026-04-17
RGN
REGENXBIO Inc.
Primary
5Y
-72.0%
3Y
-49.8%
1Y
+59.8%
6M
-19.1%
1M
+14.6%
1W
+7.8%
AQS
Aquestive Therapeutics, Inc.
Peer
5Y
-27.7%
3Y
+432.4%
1Y
+47.8%
6M
-20.4%
1M
+5.2%
1W
-4.7%
BWA
BrainsWay Ltd.
Peer
5Y
+163.4%
3Y
+1289.2%
1Y
+184.8%
6M
+61.0%
1M
-3.2%
1W
-7.8%
KMD
Kamada Ltd.
Peer
5Y
+49.5%
3Y
+95.6%
1Y
+48.0%
6M
+28.6%
1M
+2.3%
1W
+0.2%
ANG
AngioDynamics, Inc.
Peer
5Y
-49.3%
3Y
+20.9%
1Y
+23.6%
6M
+7.9%
1M
+5.1%
1W
+6.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-4.32
PEG Ratio
N/A
P/B Ratio
4.7
P/S Ratio
2.87
EV/Revenue
3.05
EV/EBITDA
-3.57
Market Cap
$489.85M

Profitability

Profit margins and return metrics

Profit Margin -113.75%
Operating Margin -189.99%
Gross Margin -45.86%
ROE -107.0%
ROA -21.93%

Growth

Revenue and earnings growth rates

Revenue Growth +43.0%
Earnings Growth N/A
Q/Q Revenue Growth +43.0%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
2.54
High debt
Current Ratio
2.38
Strong
Quick Ratio
2.27
Excellent
Cash/Share
$4.46

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
80.5%
Op. Margin
-190.0%
Net Margin
-221.3%
Total Assets
$0.5B
Liabilities
$0.4B
Equity
$0.1B
Debt/Equity
3.41x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
101%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-11
$N/A
2026-03-05
$-1.3
-54.9% surprise
2025-11-06
$-1.2
+7.6% surprise
2025-08-07
$-1.38
-30.8% surprise

Healthcare Sector Comparison

Comparing RGNX against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-107.0%
This Stock
vs
-100.15%
Sector Avg
+6.8% (Above Avg)
Profit Margin
-113.75%
This Stock
vs
-13.63%
Sector Avg
+734.7% (Superior)
Debt to Equity
2.54
This Stock
vs
3.22
Sector Avg
-21.2% (Less Debt)
Revenue Growth
43.0%
This Stock
vs
121.05%
Sector Avg
-64.5% (Slower)
Current Ratio
2.38
This Stock
vs
4.55
Sector Avg
-47.6% (Weaker)

Similar Companies

Peer comparison within the same industry

RGNX REGENXBIO Inc.
BEARISH
Mkt Cap
$490M
P/E
-
ROE
-107.0%
Price
$9.49
AQST Aquestive...
BEARISH
Mkt Cap
$490M
P/E
-
ROE
-%
Price
$4.02
 Compare with RGNX
BWAY BrainsWay Ltd.
NEUTRAL
Mkt Cap
$491M
P/E
68.1
ROE
11.3%
Price
$12.26
 Compare with RGNX
KMDA Kamada Ltd.
NEUTRAL
Mkt Cap
$491M
P/E
24.3
ROE
7.6%
Price
$8.49
 Compare with RGNX
ANGO AngioDynamics, Inc.
BEARISH
Mkt Cap
$492M
P/E
-
ROE
-15.3%
Price
$11.94
 Compare with RGNX

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

PAKOLA STEPHEN J
Officer
Sell
2026-03-10
5,124 shares · $53,033
MILLS KENNETH THOMAS
Director
Option Exercise
2026-01-27
225,000 shares · $2,945,250
PAKOLA STEPHEN J
Officer
Stock Award
2026-01-06
65,847 shares
CHAN MITCHELL
Chief Financial Officer
Stock Award
2026-01-06
73,749 shares
MALZAHN CRAIG
Chief Technology Officer
Stock Award
2026-01-06
65,847 shares
SIMPSON CURRAN M
Chief Executive Officer
Stock Award
2026-01-06
144,864 shares
CHRISTMAS PATRICK J. II
Officer
Stock Award
2026-01-06
73,749 shares
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A
DEF 14A
2026-04-14

RGNX filed a definitive proxy statement on April 14, 2026, providing shareholders with necessary information to vote on matters at the company's annual meeting.

8-K
8-K
2026-03-20
10-K
10-K
2026-03-05

RGNX filed its 10-K annual report on March 5, 2026. Due to the lack of detailed content in the provided excerpts, specific financial highlights and risk factors are unavailable.

8-K
8-K
2026-03-05
8-K
8-K
2026-02-10

Regeneron Pharmaceuticals, Inc. filed an 8-K on February 10, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K
8-K
2026-01-28

RGNX filed an 8-K on January 28, 2026, likely to announce its fourth-quarter and full-year financial results.

8-K
8-K
2025-11-06

RGNX filed a Current Report on November 6, 2025, likely announcing its third-quarter financial results.

10-Q
10-Q
2025-11-06

RGNX filed its 10-Q on November 6, 2025. The provided excerpts contain no specific financial highlights or detailed risk factors beyond a reference to Item 1A.

8-K
8-K
2025-08-18

Regeneron Pharmaceuticals, Inc. filed an 8-K, likely to announce its second-quarter financial results or a material corporate development.

10-Q
10-Q
2025-08-07

RGNX filed its quarterly 10-Q report on August 7, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section for risk factors under Item 1A.

8-K
8-K
2025-08-07
8-K
8-K
2025-06-03
8-K
8-K
2025-05-19
10-Q
10-Q
2025-05-12
8-K
8-K
2025-05-12
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
11 analysts
HC Wainwright & Co.
2026-03-09
Maintains
Buy Buy
Morgan Stanley
2026-03-06
Maintains
Overweight Overweight
HC Wainwright & Co.
2026-02-10
Maintains
Buy Buy
Goldman Sachs
2026-02-10
Maintains
Neutral Neutral
Morgan Stanley
2026-02-10
Maintains
Overweight Overweight
Chardan Capital
2026-02-10
Maintains
Buy Buy
Chardan Capital
2026-01-29
Maintains
Buy Buy
Stifel
2025-12-19
Maintains
Buy Buy
Leerink Partners
2025-12-15
Maintains
Outperform Outperform
Chardan Capital
2025-11-20
Maintains
Buy Buy

Past News Coverage

Recent headlines mentioning RGNX from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile